// App-Quantinova.ai

: RARE-45. ACTIVITY OF LAROTRECTINIB IN TRK FUSION CANCER PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM TUMORS

Researchers

Presenter

  • Sebastien Perreault

Principal Investigators

  • Michael Capra

  • Shivani Nanda

  • Nicoletta Brega

  • Ariadna Holynskyj

  • David S Ziegler

  • David S Hong

  • David M Hyman

  • Alexander Drilon

Medical Centers

  • CHU St. Justine, Montreal, Canada

  • Our Lady's Children's Hospital, Dublin, Ireland

  • Bayer HealthCare Pharmaceuticals, Whippany, NJ

  • Sydney Children's Hospital, Randwick, Australia

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • Canada

  • Ireland

  • United States

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Neurotrophic tropomyosin receptor kinase

Drug/Treatment

  • Larotrectinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02576431

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved